LIR 生命科学开始动物研究 无针肥胖药物的交付 和保障市场交易。 LIR Life Sciences starts animal study on needle-free obesity drug delivery and secures market-making deal.

LIR生命科学已开始对受控动物进行研究,测试一种无针、中转性交付方法,为第二代GLP/GIP肥胖疗法使用细胞穿透性浸药。 LIR Life Sciences has begun a controlled animal study testing a needle-free, transdermal delivery method using cell-penetrating peptides for second-generation GLP/GIP obesity therapies. 该研究通过在遇到挑战后测量葡萄糖控制情况,将专题配方与标准次皮注射法进行比较,目的是确定皮肤用药的交付是否与注射效果相匹配。 The study compares a topical formulation to standard subcutaneous injections by measuring glucose control after a challenge, aiming to determine if skin-applied delivery can match injection effectiveness. 研究评估了该平台在多种基蛋白疗法中的潜力, 支持未来开发患者友好的治疗方法. The research evaluates the platform’s potential across multiple incretin therapies, supporting future development of patient-friendly treatments. 另外,LIR还宣布与比较方案证券公司签订为期四个月的CSE市场化协议,采用自动算法,以每月收费和自动续期的方式保持流动性。 Separately, LIR announced a four-month market-making agreement with ICP Securities Inc. on the CSE, using an automated algorithm to maintain share liquidity with a monthly fee and automatic renewals.